Mounjaro 15 mg/0.5 mL pre-filled single-dose pen

Mounjaro 15 mg/0.5 mL pre-filled single-dose pen

 Mounjaro® (tirzepatide) is a once-weekly injectable medication indicated for adults with type 2 diabetes mellitus to improve blood sugar levels in combination with diet and exercise. It is the first and only medication in its class, acting as a dual GIP and GLP-1 receptor agonist. The 15 mg/0.5 mL pen is the highest available dose and is typically used as the final step in the treatment titration process for patients who have tolerated and responded well to lower doses.

Tirzepatide works by mimicking the action of two natural incretin hormones, helping the body to release more insulin when needed, reduce the amount of sugar produced by the liver, slow down digestion, and promote a sense of fullness — which may also support weight loss.

Administration Details:
Each 15 mg pen contains 0.5 mL of solution and is designed for a single subcutaneous injection. The injection is given once a week, on the same day each week, and can be administered in the abdomen, thigh, or upper arm. The pen is pre-filled and ready to use, requiring no mixing or dose calculation. It’s intended for self-injection after proper training by a healthcare provider.

Storage Instructions:
Mounjaro pens should be stored in the refrigerator between 36°F and 46°F (2°C to 8°C). If needed, they can be kept at room temperature (up to 86°F or 30°C) for a maximum of 21 days. Do not freeze the pen or expose it to excessive heat or direct sunlight.

Important Safety Information:
Mounjaro is not for use in people with type 1 diabetes or for the treatment of diabetic ketoacidosis. It should not be used in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, decreased appetite, and constipation. Serious risks may include pancreatitis, kidney issues, gallbladder problems, and a potential risk of thyroid C-cell tumors.

Clinical Use:
The 15 mg dose is generally used for patients who have completed dose escalation through 2.5 mg, 5 mg, 7.5 mg, 10 mg, and 12.5 mg. This dose provides the maximum therapeutic benefit for blood glucose control and potential weight reduction in suitable patients.